First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have become the standard of care for the first-line treatment of advanced non-small cell lung cancer patients (NSCLC), either as single agents or combined with chemotherapy. The evidence sustaining their role for poor performance status (ECOG PS ≥2) patients is limited.

Methods

We search PubMed and the proceedings of international oncology meetings to perform a systematic review to assess the outcomes poor PS NSCLC patients who received ICIs as first-line treatment. A meta-analysis included retrospective studies focusing on pembrolizumab monotherapy in PD-L1 ≥50% NSCLC. We reported the global objective response rate (ORR), disease control rate (DCR) and landmark progression-free and overall survival (PFS and OS, respectively) in

SUBMITTER: Facchinetti F 

PROVIDER: S-EPMC8264315 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature